Interferon-α plus indomethacin combined therapy in HBeAg positive chronic hepatitis B non-responder to a previous IFNα course: Results of a pilot study

International Hepatology Communications

Volumn 5, Issue 3, 1996, Pages 151-159

  Andreone, Pietro ^a   Cursaro, Carmela ^a   Gramenzi, Annagiulia ^a   Miniero, Rita ^a   Bernardi, Mauro ^a   Gasbarrini, Giovanni ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

HBV infection; Indomethacin; Interferon ; Non steroidal antiinflammatory drugs; Prostaglandins; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; RANITIDINE; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEPATITIS B; HUMAN; HYPERTHYROIDISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030197623     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/0928-4346(96)00286-1     Document Type: Article

References (22)

1. [1] Seeff LB, Koff RS. Evolving concepts of the clinical and serological consequences of hepatitis B virus infection. Semin Liver Dis 1986; 6: 11-22.
2. [2] Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-298.
3. [3] Thomas HC, Lever AM, Scully MJ, Pignatelli M. Approaches to the treatment of hepatitis B virus and delta-related liver disease. Semin Liver Dis 1986; 6: 34-41.
4. [4] Dienstag JL. Immunologic mechanisms in chronic viral hepatitis. In: Vias GN, Dienstag JL, Hoofnagie JH, eds. Viral Hepatitis and Liver Disease. New York: Grune 7 Stratton, 1984: 135-166.
5. [5] Perrillo RP, Schiff ER, Davis GL et al. A randomized controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. New Engl J Med 1990; 323: 295-301.
6. [6] Mutchnick MG, Appleman HD, Chung HT et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991; 14: 409-415.
7. [7] Dianzani F, Antonelli G, Capobianchi MR. The biological basis for clinical use of interferon. J Hepatol 1990; 11 Suppl 1: S5-S10.
8. [8] Hoofnagle JH, Peters M, Mullen KD et al. Randomized controlled trial of human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325.
9. [9] Garcia G, Smith CI, Weissberg JI et al. Adenine arabinoside monophosphate (viradabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B: a randomized, double-blinded, placebo-controlled trial. Ann Intern Med 1987; 107: 278-285.
10. [10] Andreone P, Cursaro C, Gramenzi A et al. Indomethacin increases 2′,5′-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis. Int Hepatol Commun 1994; 2: 289-294.
11. [11] Andreone P, Cursaro C, Gramenzi A et al. Indomethacin enhances serum 2′,5′-oligoadenylate synthetase in patients with HBV and HCV chronic active hepatitis. J Hepatol 1994; 21: 984-988.
12. [12] Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
13. [13] Ikeda T, Lever AML, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 1986; 6: 962-965.
14. 2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulatien of transferrin receptor expression. J Immunol 1985; 135: 1172-1179.
15. [15] Webb DR, Nowowiejski I. Mitogen-induced changes in lymphocyte prostagiandin levels: a signal for the induction of suppressor cell activity. Cell Immunol 1978; 41: 72-85.
16. [16] Whisler RL, Lindsey JA, Proctor K.VW, Morisaki N, Corwell DG. Characteristics of cyclosporine induction of increased prostaglandin levels from human peripheral blood monocytes. Transplantation 1984; 38: 377-381.
17. 2 metabolite rise in acute viral hepatitis. Dig Dis Sci 1986: 31: 349.
18. 2 on defective interferon-γ production during type B acute viral hepatitis. Res Clin Lab 1991: 21: 111-117.
19. [19] Baskin G. Interferon signalling through arachidonic acid-dependent pathway: a clue to adjuvant therapy for chronic viral hepatitis? Hepatology 1991: 14: 392-394.
20. 2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to Interferon? J Hepatol 1993; 19: 228-231.
21. [21] Andreone P, Cursaro C, Gasbarrini G. Interferon-α therapy combined with nonsteroid antiinfiammatory drugs for treatment of chronic viral hepatitis? Hepatology 1992; 16: 505.
22. [22] Andreone P, Cursaro C, Buzzi A, Miniero R, Sprovieri G, Gasbarrini G. Indomethacin enhances antiviral and immune response of patients with HBV or HCV CAH. Gastroenterology 1993; 104: A870.